[Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug]

Arch Bronconeumol. 2007 Sep;43(9):519-22. doi: 10.1016/s1579-2129(07)60118-9.
[Article in Spanish]


We report a case of pleural effusion, pericardial thickening, and pulmonary involvement in a patient with dry cough, dyspnea, edema, and changes in the skin of the lower limbs. Treatment with cabergoline (Sogilen) had been started 4 months earlier. Pleural effusion, pericardial thickening, and impaired pulmonary function (airflow obstruction, increased airway resistance, and reduced carbon monoxide diffusing capacity) were observed. The Naranjo scale pointed to a probable relationship between cabergoline and these adverse effects. We report on outcome after 2 months of follow-up, during which time there was a slow and incomplete improvement in respiratory function. This is the first case in our practice setting of early pleuropulmonary toxicity associated with cabergoline.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antiparkinson Agents / adverse effects*
  • Cabergoline
  • Ergolines / adverse effects*
  • Humans
  • Lung Diseases / chemically induced*
  • Male
  • Pleural Effusion / chemically induced*
  • Time Factors


  • Antiparkinson Agents
  • Ergolines
  • Cabergoline